Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics

Methods

Volumn 57, Issue 3, 2012, Pages 376-382

  Wiench, Benjamin ^a   Eichhorn, Tolga ^a   Korn, Bernhard ^b   Paulsen, Malte ^b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Institute of Molecular Biology GGmbH   (Germany)

Author keywords

Cytotoxicity; Drug uptake; FACS; High throughput; Inherent fluorescence; Real time

Indexed keywords

DOXORUBICIN; ETOPOSIDE; IRINOTECAN; METHOTREXATE; MITOXANTRONE; TOPOTECAN;

ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MAMMAL CELL; PRIORITY JOURNAL; PROCESS DESIGN; QUANTITATIVE ANALYSIS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENCE; HUMANS; KINETICS; MITOXANTRONE; REACTIVE OXYGEN SPECIES; SINGLE-CELL ANALYSIS;

MAMMALIA;

EID: 84865597512     PISSN: 10462023     EISSN: 10959130     Source Type: Journal    
DOI: 10.1016/j.ymeth.2012.01.007     Document Type: Article

References (25)

1. Torchilin V.P. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
2. Shen F., Chu S., Bence A.K., Bailey B., Xue X., Erickson P.A., Montrose M.H., Beck W.T., Erickson L.C. J. Pharmacol. Exp. Ther. 2008, 324:95-102.
3. Newman D.J., Cragg G.M. J. Nat. Prod. 2007, 70:461-477.
4. Egorin M.J., Hildebrand R.C., Cimino E.F., Bachur N.R. Cancer Res. 1974, 34:2243-2245.
5. Gryczynski I., Gryczynski Z., Lakowicz J.R., Yang D., Burke T.G. Photochem. Photobiol. 1999, 69:421-428.
6. Schuurhuis G.J., van Heijningen T.H.M., Cervantes A. Br. J. Cancer 1993, 68:898-908.
7. K. Effenberger-Neidnicht, S. Breyer, K. Mahal, F. Sasse, R. Schobert, Cancer Chemother Pharmacol, (2011).
8. Blumenthal R.D., Goldenberg D.M. Mol. Biotechnol. 2007, 35:185-197.
9. Bass D.A., Parce J.W., Dechatelet L.R., Szejda P., Seeds M.C., Thomas M. J. Immunol. 1983, 130:1910-1917.
10. Cossarizza A., Ferraresi R., Troiano L., Roat E., Gibellini L., Bertoncelli L., Nasi M., Pinti M. Nat. Protoc. 2009, 4:1790-1797.
11. Zhao Y., McLaughlin D., Robinson E., Harvey A.P., Hookham M.B., Shah A.M., McDermott B.J., Grieve D.J. Cancer Res. 2010, 70:9287-9297.
12. Brown I., Ward H.W. Cancer Lett. 1977, 2:227-232.
13. Ubezio P., Civoli F. Free Radic. Biol. Med. 1994, 16:509-516.
14. Barlogie B., Drewinko B., Johnston D.A., Freireich E.J. Cancer Res. 1976, 36:1975-1979.
15. Khan J.A., Kudgus R.A., Szabolcs A., Dutta S., Wang E., Cao S., Curran G.L., Shah V., Curley S., Mukhopadhyay D., Robertson J.D., Bhattacharya R., Mukherjee P. PLoS One 2011, 6:e20347.
16. M. Sato, Y. Umezawa, Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics, (2005).
17. Billinton N., Barker M.G., Michel C.E., Knight A.W., Heyer W.D., Goddard N.J., Fielden P.R., Walmsley R.M. Biosens. Bioelectron. 1998, 13:831-838.
18. Ichikawa K., Eki T. J. Biochem. 2006, 139:105-112.
19. Nicholls S.B., Chu J., Abbruzzese G., Tremblay K.D., Hardy J.A. J. Biol. Chem. 2011, 286:24977-24986.
20. Di L., Whitney-Pickett C., Umland J.P., Zhang H., Zhang X., Gebhard D.F., Lai Y., Federico J.J., Davidson R.E., Smith R., Reyner E.L., Lee C., Feng B., Rotter C., Varma M.V., Kempshall S., Fenner K., El-Kattan A.F., Liston T.E., Troutman M.D. J. Pharm. Sci. 2011, 100:4974-4985.
21. Cars O., Hedin A., Heddini A. Drug Resist. Updat. 2011, 14:68-69.
22. Indran I.R., Tufo G., Pervaiz S., Brenner C. Biochim. Biophys. Acta 2011, 1807:735-745.
23. C.P. Wu, C.H. Hsieh, Y.S. Wu, Mol Pharm, (2011).
24. Kern W., Haferlach C., Schnittger S., Haferlach T. Cancer 2010, 116:4549-4563.
25. Tiyanont K., Doan T., Lazarus M.B., Fang X., Rudner D.Z., Walker S. Proc. Natl. Acad. Sci. USA 2006, 103:11033-11038.